The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Expands robotics to 20+ specialities
The new project further expands the partner's long-term collaboration on new technologies for R&D
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Acquisition expands Merck’s growing hematology portfolio
Revenue is up 23% whereas Profit After Tax expands 29% for the company
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Subscribe To Our Newsletter & Stay Updated
